Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

SARS-CoV-2 IgM Antibody ELISA Kit

Dieses Colorimetric ELISA-Kit wurde entwickelt für die quantitative Messung von Human und SARS Coronavirus-2 (SARS-CoV-2) . Es sind 5 Publikationen verfügbar.
Produktnummer ABIN6952526

Kurzübersicht für SARS-CoV-2 IgM Antibody ELISA Kit (ABIN6952526)

Target

SARS-CoV-2 IgM Antibody

Reaktivität

Human, SARS Coronavirus-2 (SARS-CoV-2)

Nachweismethode

Colorimetric

Methodentyp

Sandwich ELISA

Applikation

ELISA

Proben

Serum
  • Verwendungszweck

    Enzyme Linked Immunosorbent Assays (ELISA) for the qualitative detection of the COVID-19 IgM in human serum.

    Analytische Methode

    Qualitative

    Produktmerkmale

    gM is first immunoglobulin to be produced in response to an antigen and will be primarily detectable during the early onset of the disease. IgM antibodies begin to show positive after 3-5 days of onset.

    Bestandteile

    • COVID-19 IgM coated Microplate
    • COVID-19 IgM Sample Diluent
    • HRP labeled COVID-19 Antigen
    • ELISA Wash Concentrate
    • ELISA HRP Substrate
    • ELISA Stop Solution
    • COVID-19 IgM Negative Control
    • COVID-19 IgM Positive Control

    Benötigtes Material

    • Precision single channel pipettes capable of delivering 10 µL, 25 µL, 100 µL, and 1000 µL, etc.
    • Repeating dispenser suitable for delivering 100 µL.
    • Disposable pipette tips suitable for above volume dispensing.
    • Disposable 12 x 75 mm or 13 x 100 glass tubes.
    • Disposable plastic 1000 mL bottle with caps.
    • Aluminum foil.
    • Deionized or distilled water.
    • Plastic microtiter well cover or polyethylene film.
    • ELISA multichannel wash bottle or automatic (semi-automatic) washing system.
    • Spectrophotometric microplate reader capable of reading absorbance at 450 nm.
  • Applikationshinweise

    National Health Commission of the People's Republic of China states that IgM antibodies begin to show positive after 3-5 days of onsett of COVID-19

    Plattentyp

    Pre-coated

    Protokoll

    Assay controls and samples are added to the microtiter wells of a microplate that was coated with a anti-human IgM specific antibody. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (H labeled recombinant COVID-19 antigen is added to each well. After an incubation period, an immunocomplex of "Anti-hIgM antibody COVID-19 IgM antibody - HRP labeled COVID-19 antigen" is formed if there is novel coronavirus IgM antibody present in the tested materials. The unbound tracer antigen is removed by the subsequent washing step. HRP-labeled COVID-19 antigen tracer bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antigen bound to the coronavirus IgM on the wallof the microtiter well is proportional to the amount of the coronavirus IgM antibody level in the tested materials.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Lagerung

    4 °C

    Informationen zur Lagerung

    This test kit must be stored at 2 - 8°C upon receipt. For the expirati date of the kit refer to the label on the kit box. All components are stable until this expiration date.
  • Egger, Bundschuh, Wiesinger, Gabriel, Clodi, Mueller, Dieplinger: "Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma." in: Clinica chimica acta; international journal of clinical chemistry, Vol. 509, pp. 18-21, (2020) (PubMed).

    Bundschuh, Egger, Wiesinger, Gabriel, Clodi, Mueller, Dieplinger: "Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma." in: Clinica chimica acta; international journal of clinical chemistry, Vol. 509, pp. 79-82, (2020) (PubMed).

    Hubiche, Le Duff, Chiaverini, Giordanengo, Passeron: "Negative SARS-CoV-2 PCR in patients with chilblain-like lesions." in: The Lancet. Infectious diseases, (2020) (PubMed).

    Charlton, Kanji, Johal, Bailey, Plitt, MacDonald, Kunst, Buss, Burnes, Fonseca, Berenger, Schnabl, Hu, Stokes, Zelyas, Tipples: "Evaluation of six commercial mid to high volume antibody and six point of care lateral flow assays for detection of SARS-CoV-2 antibodies." in: Journal of clinical microbiology, (2020) (PubMed).

    Baron, Risch, Weber, Thiel, Grossmann, Wohlwend, Lung, Hillmann, Ritzler, Bigler, Egli, Ferrara, Bodmer, Imperiali, Heer, Renz, Flatz, Kohler, Vernazza, Kahlert, Paprotny, Risch: "Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study." in: Clinical chemistry and laboratory medicine, (2020) (PubMed).

  • Target

    SARS-CoV-2 IgM Antibody

    Substanzklasse

    Antibody
Sie sind hier:
Chat with us!